Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent(Erasmus MC Cancer Institute), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Mathilde C.M. Kouwenhoven, M. Frénay(Medisch Centrum Haaglanden), Jean-Paul Armand(Medisch Centrum Haaglanden), R. Rampling(Cancer Research UK), Martin Taphoorn(Leiden University Medical Center), Barbara Klughammer(Roche (Switzerland)), Mario Campone(Institut de Cancérologie de l'Ouest), Johan M. Kros(Erasmus MC), Alain Carpentier(Hôpital Saint-Louis), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Denis Lacombe(Medisch Centrum Haaglanden), Paul M. Clément(Universitair Ziekenhuis Leuven), Alicia Tosoni(Medisch Centrum Haaglanden), Heidemarie Kletzl(Roche (Switzerland))
Cited by 573
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k